Title :

Transcatheter aortic valve implantation versus redo surgery for failing surgical aortic bioprostheses: a multicentre propensity score analysis

Author(s) :

Spaziano, Marco [Auteur]
Mylotte, Darren [Auteur]
Theriault-Lauzier, Pascal [Auteur]
De Backer, Ole [Auteur]
Sondergaard, Lars [Auteur]
Bosmans, Johan [Auteur]
Debry, Nicolas [Auteur]
Modine, Thomas [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U1171
Troubles cognitifs dégénératifs et vasculaires - U 1171 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U 1171 [TCDV]
Barbanti, Marco [Auteur]
Tamburino, Corrado [Auteur]
Sinning, Jan-Malte [Auteur]
Grube, Eberhard [Auteur]
Nickenig, Georg [Auteur]
Mellert, Fritz [Auteur]
Bleiziffer, Sabine [Auteur]
Lange, Rudiger [Auteur]
De Varennes, Benoit [Auteur]
Lachapelle, Kevin [Auteur]
Martucci, Giuseppe [Auteur]
Piazza, Nicolo [Auteur]

Journal title :

EuroIntervention . journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology

Abbreviated title :

EuroIntervention

Volume number :

13

Pages :

1149-1156

Publication date :

2017-11-01

ISSN :

1774-024X

English keyword(s) :

valve restenosis
valve-in-valve
prior cardiovascular surgery

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

OBJECTIVE: Transcatheter aortic valve implantation for a failing surgical bioprosthesis (TAV-in-SAV) has become an alternative for patients at high risk for redo surgical aortic valve replacement (redo-SAVR). Comparisons ...
Show more >OBJECTIVE: Transcatheter aortic valve implantation for a failing surgical bioprosthesis (TAV-in-SAV) has become an alternative for patients at high risk for redo surgical aortic valve replacement (redo-SAVR). Comparisons between these approaches are non-existent. This study aimed to compare clinical and echocardiographic outcomes of patients undergoing TAV-in-SAV versus redo-SAVR after accounting for baseline differences by propensity score matching. RESULTS: Patients from seven centres in Europe and Canada who had undergone either TAV-in-SAV (n=79) or redo-SAVR (n=126) were identified. Significant independent predictors used for propensity scoring were age, NYHA functional class, number of prior cardiac surgeries, urgent procedure, pulmonary hypertension, and COPD grade. Using a calliper range of ±0.05, a total of 78 well-matched patient pairs were found. All-cause mortality was similar between groups at 30 days (6.4% redo-SAVR vs. 3.9% TAV-in-SAV; p=0.49) and one year (13.1% redo-SAVR vs. 12.3% TAV-in-SAV; p=0.80). Both groups also showed similar incidences of stroke (0% redo-SAVR vs. 1.3% TAV-in-SAV; p=1.0) and new pacemaker implantation (10.3% redo-SAVR vs. 10.3% TAV-in-SAV; p=1.0). The incidence of acute kidney injury requiring dialysis was numerically lower in the TAV-in-SAV group (11.5% redo-SAVR vs. 3.8% TAV-in-SAV; p=0.13). The TAV-in-SAV group had a significantly shorter median total hospital stay (12 days redo-SAVR vs. 9 days TAV-in-SAV; p=0.001). CONCLUSIONS: Patients with aortic bioprosthesis failure treated with either redo-SAVR or TAV-in-SAV have similar 30-day and one-year clinical outcomes.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
CNRS
Inserm
Université de Lille

Collections :

• Lille Neurosciences & Cognition (LilNCog) - U 1172

Research team(s) :

Troubles cognitifs dégénératifs et vasculaires

Submission date :

2019-11-27T14:29:50Z